JP2021530568A - 自閉症を処置するための組成物および方法 - Google Patents

自閉症を処置するための組成物および方法 Download PDF

Info

Publication number
JP2021530568A
JP2021530568A JP2021526193A JP2021526193A JP2021530568A JP 2021530568 A JP2021530568 A JP 2021530568A JP 2021526193 A JP2021526193 A JP 2021526193A JP 2021526193 A JP2021526193 A JP 2021526193A JP 2021530568 A JP2021530568 A JP 2021530568A
Authority
JP
Japan
Prior art keywords
tyrosine
autism
methyl
week
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530568A5 (cg-RX-API-DMAC7.html
Inventor
ホフマン,スティーブン
ロスマン,ジョン
Original Assignee
ヤモ・ファーマシューティカルズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/040,393 external-priority patent/US10751313B2/en
Application filed by ヤモ・ファーマシューティカルズ・エルエルシー filed Critical ヤモ・ファーマシューティカルズ・エルエルシー
Publication of JP2021530568A publication Critical patent/JP2021530568A/ja
Publication of JP2021530568A5 publication Critical patent/JP2021530568A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021526193A 2018-07-19 2019-07-03 自閉症を処置するための組成物および方法 Pending JP2021530568A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/040,393 2018-07-19
US16/040,393 US10751313B2 (en) 2013-10-22 2018-07-19 Compositions and methods for treating autism
PCT/US2019/040569 WO2020018291A1 (en) 2018-07-19 2019-07-03 Compositions and methods for treating autism

Publications (2)

Publication Number Publication Date
JP2021530568A true JP2021530568A (ja) 2021-11-11
JP2021530568A5 JP2021530568A5 (cg-RX-API-DMAC7.html) 2022-07-11

Family

ID=69164908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526193A Pending JP2021530568A (ja) 2018-07-19 2019-07-03 自閉症を処置するための組成物および方法

Country Status (6)

Country Link
US (1) US12150924B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823626A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530568A (cg-RX-API-DMAC7.html)
CN (1) CN112789045A (cg-RX-API-DMAC7.html)
AU (1) AU2019306092A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020018291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059323A1 (en) * 2022-09-16 2024-03-21 Halas Francis Peter Low dose, sustained release formulation for alleviating symptoms caused by increased levels of dopamine and norepinephrine
US12488022B2 (en) * 2023-11-27 2025-12-02 Capital One Services, Llc Systems and methods for identifying data labels for submitting to additional data labeling routines based on embedding clusters

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5462325A (en) * 1977-10-17 1979-05-19 Pozuelo Jose Pharmacological treatment of schizophrenia by alphaa methyllparaathyrosine
JP2018511639A (ja) * 2015-04-14 2018-04-26 スティーブン・ホフマン 自閉症を治療するための組成物及び方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
WO2001078704A2 (en) 2000-04-13 2001-10-25 Evans William T Gaba substrate and the use thereof for treating cognitive and emotional disorders
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
HK1078086A1 (en) 2003-04-09 2006-03-03 日本烟草产业株式会社 Heteroaromatic pentacyclic compound and medicinal use thereof
WO2006039691A2 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
WO2006099288A2 (en) 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
ES2327421T3 (es) 2005-03-11 2009-10-29 Gpc Biotech Ag Terapia antiproliferativa combinada que comprende satraplatino o jm118 y docetaxel.
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
AU2009221120A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
WO2010022243A1 (en) 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10751313B2 (en) * 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) * 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5462325A (en) * 1977-10-17 1979-05-19 Pozuelo Jose Pharmacological treatment of schizophrenia by alphaa methyllparaathyrosine
JP2018511639A (ja) * 2015-04-14 2018-04-26 スティーブン・ホフマン 自閉症を治療するための組成物及び方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUROPSYCHOPHARMACOLOGY, vol. 17, no. 3, JPN6023024386, 1997, pages 162 - 174, ISSN: 0005241385 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 47, JPN6023024385, 1968, pages 568 - 576, ISSN: 0005241384 *

Also Published As

Publication number Publication date
EP3823626A4 (en) 2022-03-23
WO2020018291A1 (en) 2020-01-23
EP3823626A1 (en) 2021-05-26
US20210338619A1 (en) 2021-11-04
US12150924B2 (en) 2024-11-26
AU2019306092A1 (en) 2021-02-04
CN112789045A (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
US20230310358A1 (en) Compositions And Methods For Treating Autism
US9763903B2 (en) Compositions and methods for treating intestinal hyperpermeability
JP6858131B2 (ja) 自閉症を治療するための組成物及び方法
JP2025066802A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
TW202313003A (zh) 用於治療憂鬱之組成物及方法
US20240366582A1 (en) Treatment of raynaud's disease
US20150216827A1 (en) Compositions and Methods for Treating Intestinal Hyperpermeability
CN119174751A (zh) 用于治疗焦虑相关病症的组合物和方法
JP2018150357A (ja) 治療レジメン
US10751313B2 (en) Compositions and methods for treating autism
JP2021530569A (ja) 自閉症を処置するための組成物および方法
US12150924B2 (en) Compositions and methods for treating autism
KR20260049872A (ko) 과민성 방광을 치료하기 위한 비베그론의 용도
US20240398771A1 (en) Treatment of scleroderma and raynaud's syndrome
US20240358692A1 (en) Treatment of scleroderma
WO2026085331A1 (en) Mefluleucin for use in the treatment of suicidal ideations associated with depression
HK1190945A (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240119